Connection

Yazdan Yazdanpanah to Raltegravir Potassium

Back to Details
This is a "connection" page, showing publications Yazdan Yazdanpanah has written about Raltegravir Potassium.
Yazdan Yazdanpanah
Connection Strength
0.439
Raltegravir Potassium
  1. Lack of a Clinically Significant Pharmacokinetic Interaction between Etravirine and Raltegravir Using an Original Approach Based on Drug Metabolism, Protein Binding, and Penetration in Seminal Fluid: A Pharmacokinetic Substudy of the ANRS-163 ETRAL Study. Pharmacotherapy. 2019 04; 39(4):514-520.
    View in: PubMed
    Score: 0.181
  2. Raltegravir 1200 mg once daily versus raltegravir 400 mg twice daily, with tenofovir disoproxil fumarate and emtricitabine, for previously untreated HIV-1 infection: a randomised, double-blind, parallel-group, phase 3, non-inferiority trial. Lancet HIV. 2017 11; 4(11):e486-e494.
    View in: PubMed
    Score: 0.163
  3. High rate of virologic suppression with raltegravir plus etravirine and darunavir/ritonavir among treatment-experienced patients infected with multidrug-resistant HIV: results of the ANRS 139 TRIO trial. Clin Infect Dis. 2009 Nov 01; 49(9):1441-9.
    View in: PubMed
    Score: 0.094
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.